Comment on

• 'Nocturomics': transition to omics-driven biomarkers of nocturia, a systematic review and future prospects.

  Gong S, Bou Kheir G, Kabarriti A, Khosla L, Gong F, Van Laecke E, Weiss J, Everaert K, Hervé F. Gong S, et al. BJU Int. 2023 Jun;131(6):675-684. doi: 10.1111/bju.15975. Epub 2023 Feb 6. BJU Int. 2023. PMID: 36683403
• What's in a P-Value? A Fragility Analysis of RCTs in the AUA Guidelines for Benign Prostatic Hyperplasia.

  Anderson RM, Peña A, Johnson BS, Nowlin R, Hudson T, Vassar M. Anderson RM, et al. Urology. 2023 Jun;176:127-136. doi: 10.1016/j.urology.2022.12.063. Epub 2023 Mar 7. Urology. 2023. PMID: 36894031
• Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis.

  Baboudjian M, Gondran-Tellier B, Dariane C, Fiard G, Fromont G, Rouprêt M, Ploussard G. Baboudjian M, et al. JAMA Oncol. 2023 Jun 1;9(6):847-850. doi: 10.1001/jamaoncol.2023.0260. JAMA Oncol. 2023. PMID: 37079318 Free PMC article.
• Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study.

  Ito H, Negoro H, Kono J, Hayata N, Miura T, Manabe Y, Miyazaki Y, Mishina M, Woo JT, Sakane N, Okuno H. Ito H, et al. J Clin Med. 2023 Apr 7;12(8):2757. doi: 10.3390/jcm12082757. J Clin Med. 2023. PMID: 37109094 Free PMC article.